

Improving treatment selection for head and neck cancers and dysplasia

Submission date 02/02/2012	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 29/02/2012	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 01/12/2016	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Background and study aims

Head and neck cancer (HNC) and its treatments have considerable quality of life effects and therapeutic, rehabilitative and social costs for patient and NHS. Survival is relatively poor and has not improved a lot despite a choice of new treatments. Therefore there is a need to improve health outcomes. One of the main reasons for the problems above is that tumours have different biological characteristics. There is a need for better methods of prognostication and treatment selection taking into account the biological characteristics of disease. Recently there have been several publications showing that certain immunohistological biomarkers strongly predict response to chemoradiotherapy and significantly enhanced survival in cohorts of patients that have been recruited during RCTs. These include HPV, p16, EGFR and Bcl-2, CA-9. These studies have involved single or at most two markers at a time, and have not incorporated other known established prognostic factors such as stage of disease or smoking status. Further more these findings have not been validated independently on other cohorts. The aim of the study is to identify markers that can be used to determine whether patients with oropharyngeal cancer will respond to certain treatments before they receive their treatments. This will mean that patients will receive the most appropriate treatment and this would likely result in the best outcome for them.

Who can participate?

Any patient who has had treatment for oropharyngeal cancer

What does the study involve?

The samples and information of the treatment for that patient will be obtained from their base hospital. The samples will then be tested for the biomarkers that are being studied. The results will then be analysed to see if the biomarkers can predict the response from the treatment that the patient had.

What are the possible benefits and risks of participating?

Since this is a retrospective study that looks at what treatments patients already have, then there is no risk to patients. The benefits are that the results may help future patients.

Where is the study run from?

The study is run from the Institute of Head and Neck Studies and Education at the University Hospitals Coventry.

When is study starting and how long is it expected to run for?

The study starts in May 2012 and is running for two years.

Who is funding the study?

Cancer Research UK

Who is the main contact?

Gemma Jones

Gemma.Jones@uhcw.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Mrs Gemma Jones

Contact details

University Hospitals Coventry & Warwick

Clifford Bridge Road

Coventry

United Kingdom

CV2 2DX

+44 2476 964 000

Gemma.Jones@uhcw.nhs.uk

Additional identifiers

Protocol serial number

11317

Study information

Scientific Title

Improving treatment selection using PREDICTive and prognostic classifiers of Treatment Response for Head and Neck Cancers and dysplasia

Acronym

PREDICTR-HNC

Study objectives

Aims: The project will validate the use of molecular biomarkers to better select the management of individual patients with oropharyngeal cancer. This should improve survival and quality of care because patients will receive the treatments most likely to help them and avoid the unnecessary toxicity, morbidity and cost of potentially ineffective treatment.

Objectives: To develop and validate biomarker prognostic (PC) and treatment response classifiers (TRC) to select those patients with oropharyngeal cancers most likely to respond to chemoradiotherapy or surgery. A PC and TRC are mathematical functions that translates clinical factors and biomarker values into a set of prognostic and predictive outcomes, which select and stratify patients for treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee Covenry & Warwickshire, 14 November 2011 ref: 10/H1210/9

Primary study design

Observational

Study design

Observational study

Study type(s)

Screening

Health condition(s) or problem(s) studied

Head and neck cancer

Interventions

The outcome data and samples of patients with oropharyngeal cancer receiving either chemoradiotherapy or surgery plus or minus chemo-radiotherapy are collated from each centre. Samples are then analysed using the selected biomarkers. Complex bioinformatics analysis is then undertaken to look at the prognostic and predictive effects of selected biomarkers.

Followed up for 36 months.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Survival measured at the end of the study

Key secondary outcome(s)

No secondary outcome measures

Completion date

21/04/2014

Eligibility

Key inclusion criteria

1. Oropharyngeal (tonsil or base of tongue) squamous carcinoma
2. Has a minimum 3 year follow up or to recurrence or death if occurred before 3 years
3. Treatment by chemoradiotherapy or by surgery +/- post operative RT or chemoradiotherapy
4. Has clinical data including TNM staging available
5. Formalin fixed, paraffin embedded tissue block available
6. Male & female participants

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. No follow-up data
2. Not of stated primary site

Date of first enrolment

01/05/2012

Date of final enrolment

21/04/2014

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Clifford Bridge Road

Coventry

United Kingdom

CV2 2DX

Sponsor information

Organisation

University Hospitals Coventry & Warwick (UK)

ROR

<https://ror.org/025n38288>

Funder(s)**Funder type**

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary